FDA MedWatch: Trasylol (aprotinin injection) – FDA requests marketing suspension and Bayer Pharmaceutical Corp. has agreed, pending a detailed review of preliminary results from a Canadian study that suggested an increased risk for death
MedWatch – The FDA Safety Information and Adverse Event Reporting Program
FDA announced that, at the agency's request, Bayer Pharmaceuticals Corp. has agreed to a marketing suspension of Trasylol (aprotinin injection), a drug used to control bleeding during heart surgery, pending detailed review of preliminary results from a Canadian study that suggested an increased risk for death. FDA requested the suspension in the interest of patient safety based on the serious nature of the outcomes suggested in the preliminary data. FDA has not yet received full study data but expects to act quickly with Bayer, the study's researchers at the Ottawa Health Research Institute, and other regulatory agencies to undertake a thorough analysis of data to better understand the risks and benefits of Trasylol.
Until FDA can review the data from the terminated study it is not possible to determine and identify a population of patients undergoing cardiac surgery for which the benefits of Trasylol outweigh the risks.
However, understanding that individual doctors may identify specific cases where benefit outweighs risk, FDA is committed to exploring ways for those doctors to have continued, limited access to Trasylol. There are not many treatment options for patients at risk for excessive bleeding during cardiac surgery. Thus, FDA is working with Bayer to phase Trasylol out of the marketplace in a way that does not cause shortages of other drugs used for this purpose.
Read the complete MedWatch 2007 Safety Summary including a link to the "FDA News" and Drug Information Page, at:
http://www.fda.gov/medwatch/safety/2007/safety07.htm#Trasylol
